Letters21 January 2014Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney DiseaseKevin F. Erickson, MD, MS, Glenn M. Chertow, MD, MPH, and Jeremy D. Goldhaber-Fiebert, PhDKevin F. Erickson, MD, MSFrom Stanford University, Stanford, California.Search for more papers by this author, Glenn M. Chertow, MD, MPHFrom Stanford University, Stanford, California.Search for more papers by this author, and Jeremy D. Goldhaber-Fiebert, PhDFrom Stanford University, Stanford, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L14-5001-7 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree with Drs. Lineen and Naimark that the eGFR is an imperfect surrogate for the actual GFR and that decreases in the GFR are not identical to those in the eGFR. The treatment benefit that the TEMPO trial investigators describe may also seem greater when assessed using the eGFR instead of the true GFR, although measuring the latter would have been challenging given the relative large sample size and dispersed geography described in this trial.The eGFR necessarily introduces regression error. Ideally, we could relate our model inputs (for example, mortality rates, health-related quality of life, and ...Reference1. Campbell EG, Pham-Kanter G, Vogeli C, Iezzoni LI. Physician acquiescence to patient demands for brand-name drugs: results of a national survey of physicians [Letter]. JAMA Intern Med. 2013;173:237-9. [PMID: 23303297] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Stanford University, Stanford, California.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-0381. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Kevin F. Erickson , Glenn M. Chertow , and Jeremy D. Goldhaber-Fiebert Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease James Lineen , David M.J. Naimark , and Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Christopher M. Blanchette , Benjamin Gutierrez , and Keith Friend Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease James Lineen , David M.J. Naimark , and Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Christopher M. Blanchette , Benjamin Gutierrez , and Keith Friend Metrics 21 January 2014Volume 160, Issue 2Page: 143KeywordsHyponatremiaKidneysLongitudinal studiesPolycystic kidney diseaseQuality of lifeRenal analysisRenal failureStatins ePublished: 21 January 2014 Issue Published: 21 January 2014 CopyrightCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Read full abstract